FilingSEC EDGAR8-K
Apimeds Pharmaceuticals Completes 1-for-10 Reverse Stock Split
· SEC accepted
StageCompleted
Filing content
Apimeds Pharmaceuticals completed a 1-for-10 reverse stock split effective July 24, 2026, and began trading on a split-adjusted basis on the NYSE American on the same day.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…